Iterum Therapeutics Public Limited Company operates as a a clinical-stage pharmaceutical company. The Company develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. Iterum Therapeutics serves physicians and patients worldwide.

Current Report (Form 8-K | Period ending 2024-12-10)

424B5 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Iterum Therapeutics (ITRM US)

Current Report (Form 8-K | Period ending 2024-12-10)

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2024-11-20)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-14)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)